



October 31, 2016

Xencor to Present at Upcoming Investor Conferences

MONROVIA, Calif., Oct. 31, 2016 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will present a corporate overview at two upcoming conferences:

- | **25th Annual Credit Suisse Healthcare Conference**

Date: Monday, November 7, 2016

Time: 4:00 p.m. MT

Location: Scottsdale, AZ

- | **28th Annual Piper Jaffray Healthcare Conference**

Date: Wednesday, November 30, 2016

Time: 10:00 a.m. ET

Location: New York, NY

Live webcasts of both events will be available on the "Events & Presentations" section in the Investors section of the Company's website located at <http://investors.xencor.com/events.cfm>. A replay of the presentations will be posted on the Xencor website approximately one hour after the live events and will be available for 30 days following the presentations.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Currently, 10 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's internal programs include: XmAb5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb7195 in Phase 1 development for the treatment of asthma and allergic diseases; XmAb14045 in Phase 1 development for acute myeloid leukemia; and XmAb13676 for B-cell malignancies and XmAb18087 for the treatment of neuroendocrine tumors, both in pre-clinical development. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Novartis, Amgen, MorphoSys, Merck, CSL/Janssen, Alexion, Novo Nordisk and Boehringer Ingelheim. For more information, please visit www.xencor.com.

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/xencor-to-present-at-upcoming-investor-conferences-300353684.html>

SOURCE Xencor, Inc.

News Provided by Acquire Media